Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study

Fred Poordad, Kosh Agarwal, Ziad Younes, Daniel Cohen, Wangang Xie, Thomas Podsadecki

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.

Original languageEnglish (US)
Pages (from-to)608-610
Number of pages3
JournalClinical Infectious Diseases
Volume60
Issue number4
DOIs
StatePublished - Feb 15 2015

Keywords

  • concordance
  • direct-acting antivirals
  • hepatitis C
  • sustained virologic response

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infection in the AVIATOR study'. Together they form a unique fingerprint.

  • Cite this